{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"
Neuer zielgerichteter Therapieansatz beim IDH1 R132- mutierten Cholangiokarzinom
Evaluation der Wirksamkeit, Sicherheit und Lebensqualität der Behandlung mit Ivosidenib
","eudractNumber":null,"id":11564,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-10-06T09:14:01+02:00","shortTitle":"IDHIRA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
Phase 1 study evaluating genetically modified autologous T cells expressing a T cell recepter recognizing a cancer/germline Antigen in patients with recurrent and/or refractory solid Tumors (ACTengine IMA203-101)

Target: PRAME
","eudractNumber":"2019-002370-31","id":5992,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PRAME (Nuclear Receptor Transcriptional Regulator)","id":"mt_171"},{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"}],"nctNumber":"NCT03686124","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2020-08-13T09:33:56+02:00","shortTitle":"IMA203-101 (Immatics-PRAME)","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"BZKF-Studie
A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients with Recurrent and/or Refractory Solid Tumors
","eudractNumber":"2021-004326-30","id":7252,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"},{"name":"MAGEA (Melanoma-associated Antigen)","id":"mt_245"},{"name":"MAGEA4","id":"mt_187"},{"name":"MAGEA8","id":"mt_188"}],"nctNumber":"NCT05359445","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2022-07-18T10:30:48+02:00","shortTitle":"IMA401-101","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"Impact of premedication on anxiety: a multi-centre, prospective observational cohort study","eudractNumber":null,"id":6940,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04103723","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2021-08-26T13:03:21+02:00","shortTitle":"IMPACT","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)","eudractNumber":"2023-510292-65-00","id":11651,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06585774","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-01T12:53:35+01:00","shortTitle":"INCA034176-357","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE)
","eudractNumber":"2021-000330-33","id":6920,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym2","name":"Morbus Hodgkin"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04837859","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-12-06T13:28:10+01:00","shortTitle":"INDIE","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Klinische Forschungsplattform zur \nErfassung der Entscheidungsfindung in der Biomarker-basierten \nPräzisionsonkologie und deren klinische Bedeutung","eudractNumber":null,"id":5702,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04389541","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-07-13T08:22:15+02:00","shortTitle":"INFINITY","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)","eudractNumber":"2023-505306-42","id":9869,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"},{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"}],"nctNumber":"NCT06112314","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-06T09:44:34+01:00","shortTitle":"Immunocore IMC-F106C-301","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"The Registry of the European Mantle Cell Lymphoma Network (EMCL-R)","eudractNumber":null,"id":8672,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-01-24T11:07:40+01:00","shortTitle":"International MCL Registry (EMCL-R)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Nicht-interventionelle Beobachtungsstudie zur Bewertung der Lebensqualität (HRQoL) bei Patienten mit rezidiviertem und/oder refraktärem Multiplen Myelom, die eine vorherige Therapielinie erhalten haben und mit Isatuximab behandelt werden.","eudractNumber":null,"id":11929,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-12T08:47:20+01:00","shortTitle":"IsaPRO","therapeutical":false,"therapyLines":[]}]}